Drugs / YCT-529
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06542237 | Sep 2024 → Jul 2026 overdue | — | YourChoice Therapeutics, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06094283 Comparator | Dec 2023 → Jun 2024 | — | YourChoice Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YCT-529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06542237 ↗ |
| Known as | Yct-529 free acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL5499704 ↗ |
| Action | Inhibit | “YCT-529 - a retinoic acid receptor-α antagonist” PMID 40696162 ↗ Jul 2025 |
| Modality | Small molecule | “The small molecule YCT-529 stops sperm production” PMID 40696162 ↗ Jul 2025 |
| Route | Oral | “single oral doses of 10, 30, 90 or 180 mg of YCT-529 in the fasted state” PMID 40696162 ↗ Jul 2025 |
| Target | RARA | “YCT-529 - a retinoic acid receptor-α antagonist” PMID 40696162 ↗ Jul 2025 |